Therapeutic Efficacy and Resistance Selection of a Lipopeptide Fusion Inhibitor in Simian Immunodeficiency Virus-Infected Rhesus Macaques
- 1 July 2020
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 94 (15)
- https://doi.org/10.1128/JVI.00384-20
Abstract
We recently reported a group of lipopeptide-based membrane fusion inhibitors with potent antiviral activities against human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIV). In this study, the in vivo therapeutic efficacy of such a lipopeptide, LP-52, was evaluated in rhesus macaques chronically infected with pathogenic SIVmac239. In a pilot study with one monkey, monotherapy with low-dose LP-52 rapidly reduced the plasma viral loads to below the limit of detection and maintained viral suppression during three rounds of structurally interrupted treatment. The therapeutic efficacy of LP-52 was further verified in four infected monkeys; however, three out of the monkeys had viral rebounds under the LP-52 therapy. We next focused on characterizing SIV mutants responsible for the in vivo resistance. Sequence analyses revealed that a V562A or V562M mutation in the N-terminal heptad repeat (NHR) and a E657G mutation in the C-terminal heptad repeat (CHR) of SIV gp41 conferred high resistance to LP-52 and cross-resistance to the peptide drug T20 and two newly designed lipopeptides (LP-80 and LP-83). Moreover, we showed that the resistance mutations greatly reduced the stability of diverse fusion inhibitors with the NHR site, and V562A or V562M in combination with E657G could significantly impair the functionality of viral envelopes (Envs) to mediate SIVmac239 infection and decrease the thermostability of viral six-helical bundle (6-HB) core structure. In conclusion, the present data have not only facilitated the development of novel anti-HIV drugs that target the membrane fusion step, but also help our understanding of the mechanism of viral evolution to develop drug resistance. IMPORTANCE The anti-HIV peptide drug T20 (enfuvirtide) is the only membrane fusion inhibitor available for treatment of viral infection; however, it exhibits relatively weak antiviral activity, short half-life, and a low genetic barrier to inducing drug resistance. Design of lipopeptide-based fusion inhibitors with extremely potent and broad antiviral activities against divergent HIV-1, HIV-2, and SIV isolates have provided drug candidates for clinical development. Here, we have verified a high therapeutic efficacy for the lipopeptide LP-52 in SIVmac239-infected rhesus monkeys. The resistance mutations selected in vivo have also been characterized, providing insights into the mechanism of action of newly designed fusion inhibitors with a membrane-anchoring property. For the first time, the data show that HIV-1 and SIV can share a similar genetic pathway to develop resistance, and that a lipopeptide fusion inhibitor could have a same resistance profile as its template peptide.Funding Information
- National Science and Technology Major Project of China (2018ZX10301103, 2017ZX10304402-001-011, 2017ZX10202102-001-003)
- CAMS Innovation Fund for Medical Sciences (2017-I2M-1-014)
This publication has 48 references indexed in Scilit:
- Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor SifuvirtideOnline Journal of Public Health Informatics, 2012
- In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion InhibitorOnline Journal of Public Health Informatics, 2011
- Resistance Profiles of Novel Electrostatically Constrained HIV-1 Fusion InhibitorsOnline Journal of Public Health Informatics, 2010
- Detailed Mechanistic Insights into HIV-1 Sensitivity to Three Generations of Fusion InhibitorsOnline Journal of Public Health Informatics, 2009
- Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potencyProceedings of the National Academy of Sciences of the United States of America, 2009
- HR-2 Mutations in Human Immunodeficiency Virus Type 1 gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to EnfuvirtideJournal of Virology, 2009
- Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 VariantsJournal of Virology, 2008
- Clinical Resistance to Enfuvirtide Does Not Affect Susceptibility ofHuman Immunodeficiency Virus Type 1 to Other Classes of Entry InhibitorsJournal of Virology, 2007
- The structural biology of type I viral membrane fusionNature Reviews Molecular Cell Biology, 2003
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences of the United States of America, 1994